A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07575373 |
Feasibility of an Interdisciplinary Intervention to Improve Care Transitions for Hospitalized Patients With Substance Use Disorders |
NOT_YET_RECRUITING | NA |
| NCT07555145 |
Supporting Treatment Access and Recovery in Re-entry (STAR-R) |
NOT_YET_RECRUITING | NA |
| NCT07529327 |
Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups and Individualized Services |
RECRUITING | NA |
| NCT07519759 |
Recovery Inspired Support Engagement (RISE) Pilot |
NOT_YET_RECRUITING | NA |
| NCT07499583 |
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07417579 |
Mindfulness and Meditation-Based Relapse Prevention for Substance Use Disorders |
COMPLETED | |
| NCT07395700 |
Validation of the Behavioral Activation for Depression Scale in Individuals With Substance Use Disorders |
COMPLETED | |
| NCT07387796 |
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation |
NOT_YET_RECRUITING | NA |
| NCT07364799 |
Effectiveness of the SoundHeal Multi-Sensory Integrative Therapy Among Justice-Involved Youth |
RECRUITING | NA |
| NCT07340554 |
Neuroimaging of Adolescent Cannabis Use Treatment |
RECRUITING | NA |
